CVS Health (CVS) Stock Forecast & Price Target

Compare

33 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CVS Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

CVS

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CVS Stock 12 Month Forecast

Average Price Target

€81.10

▲(22.38% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is €81.10 with a high forecast of €88.49 and a low forecast of €75.84. The average price target represents a 22.38% change from the last price of €66.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"€51","70":"€70","89":"€89","60.5":"€60.5","79.5":"€79.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":88.48558215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€88.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.1033564392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€81.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.8447847,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€75.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,60.5,70,79.5,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.22,65.16350631923076,67.10701263846154,69.0505189576923,70.99402527692308,72.93753159615385,74.88103791538461,76.82454423461539,78.76805055384615,80.71155687307692,82.6550631923077,84.59856951153846,86.54207583076924,{"y":88.48558215,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.22,64.59564280301538,65.97128560603076,67.34692840904616,68.72257121206154,70.09821401507692,71.4738568180923,72.8494996211077,74.22514242412308,75.60078522713846,76.97642803015384,78.35207083316924,79.72771363618462,{"y":81.1033564392,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.22,64.19113728461538,65.16227456923077,66.13341185384616,67.10454913846154,68.07568642307692,69.04682370769231,70.01796099230769,70.98909827692307,71.96023556153847,72.93137284615385,73.90251013076923,74.87364741538462,{"y":75.8447847,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.518,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.171,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.214,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.613,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.616,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.619,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.718,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.855,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.538,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€88.49

Average Price Target€81.10

Lowest Price Target€75.84

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Baxter

Wells Fargo

€85.93

Buy

29.66%

Upside

Reiterated

02/13/26

We update our model following 4Q25 results. Our 2026 estimates are unchanged, and we shift some MA margin recovery out from 2027 to 2028 to account for the weaker starting point on reimbursement in 2027. We maintain our $102 PT and OW rating. 2026. Our outlook for 2026 remains largely consistent following strong Q4 results and reaffirmed guidance. MA margin recovery remains key and is still on track as we see re- pricing and benefit changes play out. Mgmt noted 55% / 45% earnings cadence in 1H / 2H and 850bps spread in Q1 vs Q4 HCB MLR. For 2026: T/W include 1) 2) exit of HIX, 3) improvement in care delivery at OSH. H/W include: 1) slow growth in Caremark, expects LSD % AOI segment growth, 2) cautious Medicaid outlook. Healthcare Benefits.

David S Macdonald

Truist Financial

€82.56

Buy

24.57%

Upside

Reiterated

02/11/26

Truist Financial Remains a Buy on CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

€80.03→€84.24

Buy

27.12%

Upside

Reiterated

02/11/26

Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

Hold

―

Reiterated

02/11/26

Oppenheimer Keeps Their Hold Rating on CVS Health (CVS)

Scott Fidel

Goldman Sachs

€80.03

Buy

20.76%

Upside

Reiterated

02/10/26

CVS Health: Strong Q4 Outperformance and Reinforced 2026 Guidance Support Buy Rating

Ben Hendrix

RBC Capital

€78.34

Buy

18.22%

Upside

Reiterated

02/10/26

RBC Capital Reaffirms Their Buy Rating on CVS Health (CVS)

Sarah James

Cantor Fitzgerald

€80.03

Buy

20.76%

Upside

Reiterated

02/10/26

Cantor Fitzgerald Remains a Buy on CVS Health (CVS)

Charles Rhyee

TD Cowen

€88.45

Buy

33.47%

Upside

Reiterated

02/10/26

Buy Rating Maintained on CVS: Credible Path to Profit Growth Despite 2027 MA Headwinds and Conservative 2026 Outlook

Erin Wright

Morgan Stanley

€78.34

Buy

18.22%

Upside

Reiterated

02/03/26

Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Xenon (NASDAQ: XENE)

Allen Lutz

Bank of America Securities

€84.24→€80.03

Buy

20.76%

Upside

Reiterated

01/27/26

CVS Health (CVS) Receives a Buy from Bank of America Securities

Steven Silver

Argus Research

€76.66→€75.82

Buy

14.41%

Upside

Reiterated

01/27/26

CVS Health price target lowered to $90 from $91 at ArgusCVS Health price target lowered to $90 from $91 at Argus

Lance Wilkes

Bernstein

€76.66

Hold

15.68%

Upside

Reiterated

01/27/26

Bernstein Keeps Their Hold Rating on CVS Health (CVS)

Ann Hynes

Mizuho Securities

€80.03

Buy

20.76%

Upside

Reiterated

01/15/26

Mizuho Securities Sticks to Their Buy Rating for CVS Health (CVS)

Lisa Gill

J.P. Morgan

€78.34→€85.08

Buy

28.39%

Upside

Reiterated

12/17/25

CVS Health price target raised to $101 from $93 at JPMorganCVS Health price target raised to $101 from $93 at JPMorgan

Kevin Caliendo

UBS

€80.87→€81.71

Buy

23.30%

Upside

Reiterated

12/10/25

CVS Health: Projected Growth and Strategic Capital Deployment Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Baxter

Wells Fargo

€85.93

Buy

29.66%

Upside

Reiterated

02/13/26

David S Macdonald

Truist Financial

€82.56

Buy

24.57%

Upside

Reiterated

02/11/26

Truist Financial Remains a Buy on CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

€80.03→€84.24

Buy

27.12%

Upside

Reiterated

02/11/26

Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

Hold

―

Reiterated

02/11/26

Oppenheimer Keeps Their Hold Rating on CVS Health (CVS)

Scott Fidel

Goldman Sachs

€80.03

Buy

20.76%

Upside

Reiterated

02/10/26

CVS Health: Strong Q4 Outperformance and Reinforced 2026 Guidance Support Buy Rating

Ben Hendrix

RBC Capital

€78.34

Buy

18.22%

Upside

Reiterated

02/10/26

RBC Capital Reaffirms Their Buy Rating on CVS Health (CVS)

Sarah James

Cantor Fitzgerald

€80.03

Buy

20.76%

Upside

Reiterated

02/10/26

Cantor Fitzgerald Remains a Buy on CVS Health (CVS)

Charles Rhyee

TD Cowen

€88.45

Buy

33.47%

Upside

Reiterated

02/10/26

Buy Rating Maintained on CVS: Credible Path to Profit Growth Despite 2027 MA Headwinds and Conservative 2026 Outlook

Erin Wright

Morgan Stanley

€78.34

Buy

18.22%

Upside

Reiterated

02/03/26

Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Xenon (NASDAQ: XENE)

Allen Lutz

Bank of America Securities

€84.24→€80.03

Buy

20.76%

Upside

Reiterated

01/27/26

CVS Health (CVS) Receives a Buy from Bank of America Securities

Steven Silver

Argus Research

€76.66→€75.82

Buy

14.41%

Upside

Reiterated

01/27/26

CVS Health price target lowered to $90 from $91 at ArgusCVS Health price target lowered to $90 from $91 at Argus

Lance Wilkes

Bernstein

€76.66

Hold

15.68%

Upside

Reiterated

01/27/26

Bernstein Keeps Their Hold Rating on CVS Health (CVS)

Ann Hynes

Mizuho Securities

€80.03

Buy

20.76%

Upside

Reiterated

01/15/26

Mizuho Securities Sticks to Their Buy Rating for CVS Health (CVS)

Lisa Gill

J.P. Morgan

€78.34→€85.08

Buy

28.39%

Upside

Reiterated

12/17/25

CVS Health price target raised to $101 from $93 at JPMorganCVS Health price target raised to $101 from $93 at JPMorgan

Kevin Caliendo

UBS

€80.87→€81.71

Buy

23.30%

Upside

Reiterated

12/10/25

CVS Health: Projected Growth and Strategic Capital Deployment Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

3 Months

xxx

Success Rate

11/18 ratings generated profit

Average Return

+0.06%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +0.06% per trade.

1 Year

Elizabeth Anderson CFAEvercore ISI

Success Rate

15/22 ratings generated profit

Average Return

+15.21%

reiterated a buy rating 6 days ago

Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +15.21% per trade.

2 Years

xxx

Success Rate

19/22 ratings generated profit

Average Return

+22.17%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.36% of your transactions generating a profit, with an average return of +22.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CVS has received 33 Buy Ratings, 25 Hold Ratings, and 0 Sell Ratings. CVS average Analyst price target in the past 3 months is 81.10.

Each month's total comprises the sum of three months' worth of ratings.

CVS Financial Forecast

CVS Earnings Forecast

Next quarter’s earnings estimate for CVS is €1.88 with a range of €1.77 to €2.00. The previous quarter’s EPS was €0.92. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Sales Forecast

Next quarter’s sales forecast for CVS is €80.75B with a range of €77.66B to €84.94B. The previous quarter’s sales results were €89.02B. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Stock Forecast FAQ

What is DE:CVS’s average 12-month price target, according to analysts?

Based on analyst ratings, CVS Health Corp’s 12-month average price target is 81.10.

What is DE:CVS’s upside potential, based on the analysts’ average price target?

CVS Health Corp has 22.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CVS Health Corp a Buy, Sell or Hold?

CVS Health Corp has a consensus rating of Strong Buy, which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is CVS Health Corp’s share price target?

The average share price target for CVS Health Corp is 81.10. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €88.49 ,and the lowest forecast is €75.84. The average share price target represents 22.38% Increase from the current price of €66.27.

What do analysts say about CVS Health Corp?

CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of CVS Health Corp?

To buy shares of DE:CVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

CVS Health (CVS) Stock Forecast & Price Target

CVS Analyst Ratings

CVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CVS Health

CVS Analyst Recommendation Trends

CVS Financial Forecast

CVS Earnings Forecast

CVS Sales Forecast

CVS Stock Forecast FAQ

Detailed List of Analyst Forecasts